- Home
- CGEN vs EVG Comparison
CGEN vs EVG Comparison
Compare CGEN & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- EVG
- Stock Information
- Founded
- CGEN 1993
- EVG 2005
- Country
- CGEN Israel
- EVG United States
- Employees
- CGEN N/A
- EVG N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- EVG Investment Managers
- Sector
- CGEN Health Care
- EVG Finance
- Exchange
- CGEN Nasdaq
- EVG Nasdaq
- Market Cap
- CGEN 167.4M
- EVG 148.1M
- IPO Year
- CGEN 2000
- EVG N/A
- Fundamental
- Price
- CGEN $1.43
- EVG $11.33
- Analyst Decision
- CGEN
- EVG
- Analyst Count
- CGEN 0
- EVG 0
- Target Price
- CGEN N/A
- EVG N/A
- AVG Volume (30 Days)
- CGEN 217.0K
- EVG 49.4K
- Earning Date
- CGEN 08-06-2025
- EVG 01-01-0001
- Dividend Yield
- CGEN N/A
- EVG 8.68%
- EPS Growth
- CGEN N/A
- EVG N/A
- EPS
- CGEN N/A
- EVG N/A
- Revenue
- CGEN $22,144,000.00
- EVG N/A
- Revenue This Year
- CGEN N/A
- EVG N/A
- Revenue Next Year
- CGEN $105.77
- EVG N/A
- P/E Ratio
- CGEN N/A
- EVG N/A
- Revenue Growth
- CGEN N/A
- EVG N/A
- 52 Week Low
- CGEN $1.13
- EVG $9.13
- 52 Week High
- CGEN $2.66
- EVG $10.86
- Technical
- Relative Strength Index (RSI)
- CGEN 37.47
- EVG 64.02
- Support Level
- CGEN $1.43
- EVG $11.17
- Resistance Level
- CGEN $1.53
- EVG $11.45
- Average True Range (ATR)
- CGEN 0.06
- EVG 0.13
- MACD
- CGEN 0.00
- EVG 0.02
- Stochastic Oscillator
- CGEN 44.44
- EVG 73.91
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.